Tykerb Indications/Uses

Tykerb, in combination with capecitabine, is indicated for the treatment of patients with advanced or metastatic breast cancer (MBC) whose tumours overexpress ErbB2 (HER2+/neu) and whose tumour have progressed after treatment with trastuzumab (see Pharmacology: Clinical Studies under Actions).
In combination with trastuzumab, is indicated for the treatment of patients with MBC whose tumours overexpress ErbB2 (HER2/neu) and whose tumour have progressed after treatment with trastuzumab therapy(s) in the metastatic setting and for whom trastuzumab is not appropriate (see Pharmacology: Clinical Studies under Actions).
In combination with paclitaxel, is indicated for the 1st line treatment of patients with MBC whose tumours overexpress ErbB2 (HER2/neu) and for whom trastuzumab is not appropriate (see Pharmacology: Clinical Studies under Actions).
In combination with an aromatase inhibitor, is indicated for the treatment of postmenopausal women with hormone receptor-positive, ErbB2 (HER2/neu) overexpressing advanced or MBC, and for whom hormone therapy is indicated (see Pharmacology: Clinical Studies under Actions).